KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) FCF Margin (2020 - 2026)

AbCellera Biologics filings provide 7 years of FCF Margin readings, the most recent being 449.24% for Q1 2026.

  • Quarterly FCF Margin rose 7473.0% to 449.24% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 238.91% through Mar 2026, up 38101.0% year-over-year, with the annual reading at 231.69% for FY2025, 41670.0% up from the prior year.
  • FCF Margin hit 449.24% in Q1 2026 for AbCellera Biologics, down from 99.4% in the prior quarter.
  • Across five years, FCF Margin topped out at 526.37% in Q2 2022 and bottomed at 728.42% in Q3 2024.
  • Average FCF Margin over 5 years is 312.02%, with a median of 370.87% recorded in 2023.
  • The largest annual shift saw FCF Margin plummeted -61124bps in 2024 before it surged 41591bps in 2025.
  • AbCellera Biologics' FCF Margin stood at 86.25% in 2022, then crashed by -530bps to 370.87% in 2023, then dropped by -26bps to 467.92% in 2024, then soared by 79bps to 99.4% in 2025, then plummeted by -352bps to 449.24% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's FCF Margin are 449.24% (Q1 2026), 99.4% (Q4 2025), and 687.01% (Q3 2025).